November #139 : What’s In, What’s Out - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Pray Tell

The South Shall Rise Again

Coming Clean

On Your Marks

What’s In, What’s Out

Sperm of the Moment

Ready for Your Screen Test?

Staph Directory

(Not So) Free of Charge

The Simplex Life

The Big Fix


Scotch Guard

Sounds Like a Plan

I Got Tested for HIV... And All I Got Was This Lousy T-Shirt

Hot Dates-November 2007

Babe Boom

The Profiler

Hot or Not?

Release Party

Toxic Avengers

Ticket to Ride

Medical Leave

Saturday's Child

Editor's Letter-November 2007

Mailbox-November 2007

Catch of the Month-November 2007

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

November 2007

What’s In, What’s Out

by Laura Whitehorn

A timeline of HIV therapy trends

Monotherapy and combo lite: HIV wasn’t ID’d as the culprit behind AIDS until 1983, and meds to suppress the virus emerged slowly. So people had no choice but to take one or two drugs at a time, with only CD4 counts to gauge success or failure.

Hit hard, hit early with HAART (Highly Active Antiretroviral Therapy): With the approval of the first protease inhibitors and a non-nuke (Viramune/nevirapine), there were three different classes of drugs. Combining meds from several classes revolutionized treatment by disrupting HIV at various points in its reproductive cycle. Viral-load testing became available, so treatment failure could be spotted early, before CD4s began falling.

In the early days of HAART, docs put people on meds at HIV diagnosis or soon after. The theory: prolong health, and possibly eradicate the virus, by suppressing HIV as early and quickly as possible—when CD4 cells drop to 500, said U.S. treatment guidelines.

2001 to the present
Conservative HAART: Wait for CD4 counts between 200 and 350 before starting meds. This has been the standard (reflected in revised U.S. treatment guidelines) ever since adherence problems (which can lead to drug resistance) and side effects (both short- and long-term) showed the downside of HIV meds.

2007 to the future?
Hit hard/early with HAART, the sequel: As long-term studies suggest that some of what we’ve considered to be med side effects are actually damage done by HIV itself, several researchers think it’s time to begin starting meds earlier. Sound

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.